Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 March 2022 | Story André Damons
Dr Yolandi Swart
Dr Yolandi Swart, who took over from Prof Lynette van der Merwe as the new Director of the Undergraduate Medical Programme (MB ChB programme) in the School of Clinical Medicine within the Faculty of Health Sciences at the University of the Free State (UFS), says she is excited about the new opportunities that come with this position.

The new Director of the Undergraduate Medical Programme (MB ChB programme) in the School of Clinical Medicine within the Faculty of Health Sciences at the University of the Free State (UFS) has a passion for teaching and learning and brings a wealth of experience with her.

Dr Yolandi Swart, who took over from Prof Lynette van der Merwe on 1 March 2022, says she is excited about the new opportunities that this position brings. She was not actively job-hunting and came across the advertisement by accident but was thrilled when she was informed that she is the recommended candidate.

A deep love for the UFS

“I will be heading up an amazing team of people who drive the MB ChB programme, making sure that we walk with our students on their journey to become the next generation of health professionals who will contribute to the health and wellness of our population. Our functions include coordinating the undergraduate curriculum, providing student support, as well as logistic support to ensure the smooth running of the MB ChB programme,” says Dr Swart.

As an alumna of the university (she obtained both her MB ChB and postgraduate MMed in Community Health at the UFS), she has a deep love for the UFS, as it has played a huge role in developing her into the person she is today.

According to Dr Swart, she looks forward to getting to know the students and seeing them develop into the best they can be, as well as engaging with the academic staff as they guide and train the students. She brings a diverse background to the position, having practised as a doctor, specialised in Community Health, and worked in clinical research at various levels, including senior management. This has afforded her the opportunity to equip herself with skills that she hopes will provide support and direction to the Undergraduate Programme Management team in order to provide excellent service in all its functions.

Her vision

“I love teaching and learning – taking a concept and making it accessible to someone.  There are few things as satisfying as seeing that expression that says ‘Oh, now I get it!’

Kovsies has always had a reputation of producing excellent doctors.  “It is my vision to build on that reputation, integrating local and international best practices as they develop into our students’ training, with the aim of developing young professionals who are competent, resilient, and able to face the challenges that life will throw at them – so that they, in turn, can play their role to influence lives for the better.”

Prior to her appointment, she worked at FARMOVS as a clinical research physician for more than six years, the past year and a half as the company’s Medical Director. Says Dr Swart: “I love challenging myself with new things every so often. Past and present hobbies include surfing (which died an early death, as I was horrible at it), scuba diving (yes, with sharks as well), horse-riding, and self-defence.  Most recently, I got hooked on traditional archery – a very challenging skill to try and master.”

Dr Swart says she has learned throughout her personal life and professional career that life sometimes takes unexpected turns – but if one is open to the opportunities afforded by those unexpected turns, it often turns out so much better than the original plan could ever have been. “Difficulties and challenges will always come – but if one faces them with a positive attitude, they teach life skills that you would otherwise never have attained.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept